How do immune cells strike a balance, unleashing rapid attacks against pathogens or cancer, while avoiding damage to healthy ...
Scientists at the Icahn School of Medicine at Mount Sinai have developed an experimental immunotherapy that takes an ...
The FDA's breakthrough therapy designation facilitates accelerated development and regulatory review for therapies showing ...
Degrader of cancer protein IDO1 prevents cancer immune suppression by cancer and offers promising strategy to support existing immunotherapies ...
T-cell engagers are antibody-based therapeutics that can reprogram T cells for antigen-specific elimination of target cells.
Inovio Pharmaceuticals faces an October 30 PDUFA date for INO-3107 with high regulatory risk and only a 5-7 month cash runway. Read why INO stock is a hold.
Arabian Post on MSN
Breakthrough unlocks scalable helper T cell cancer therapies
Scientists have demonstrated a dependable method to generate large numbers of helper T cells from stem cells, removing a long-standing obstacle that has limited immune-based cancer treatments. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback